This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Familial haemophagocytic reticulosis가족성 혈구탐식세망증

ICD-10: D76.1 | Synonyms: FHL, Familial hemophagocytic lymphohistiocytosis, FHL1~5

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First description

Familial hemophagocytic reticulosis (FHL) was first described in 1952 by Farquhar and Claireaux. They first reported pathological findings of histiocytic proliferation, hemophagocytosis and splenomegaly in two siblings who developed the disease in infancy and died rapidly, and named it 'familial hemophagocytic reticulosis.' The name derived from the characteristic pathology at the time in which histiocytes/reticulum cells phagocytose blood cells.

Identification of genetic causes

In 1999, Stepp and colleagues identified mutations in PRF1 (perforin 1), the first causative gene of FHL, confirming at the molecular level that FHL is a hereditary immunodeficiency disorder. Subsequently, mutations in UNC13D (FHL3) in 2003, STX11 (FHL4) in 2005 and STXBP2 (FHL5) in 2009 were identified in sequence. These discoveries established that FHL is a genetic defect of the cytotoxic granule secretion pathway (perforin-granzyme pathway).

Advances in treatment

Until the 1980s, FHL was fatal in almost all cases. After Fischer and colleagues first reported long-term cure of an FHL patient by hematopoietic stem cell transplantation (HSCT) in 1986, HSCT became established as the curative treatment for primary HLH. With the HLH-94 protocol in 1994, standard induction therapy was established.

2. Causes

Genetic defects of the cytotoxic granule secretion pathway

The core cause of FHL is loss-of-function mutations in genes encoding proteins involved in the perforin-granzyme pathway, by which cytotoxic T lymphocytes (CTLs) and NK cells kill target cells. Normally, in this pathway, activated CTLs/NK cells move lytic granules to the immunological synapse and secrete them to destroy target cells.

Major causative genes

TypeGeneChromosomal locationFunctional defect
FHL1Unknown9q21.3-22Causative gene unknown
FHL2PRF110q22Loss of perforin protein function
FHL3UNC13D(MUNC13-4)17q25Impaired granule fusion
FHL4STX11(Syntaxin 11)6q24Defect in the membrane fusion step
FHL5STXBP2(MUNC18-2)19p13Loss of Syntaxin 11 stabilizing function

Environmental triggers

In patients with FHL, infection (especially EBV, CMV, influenza) often acts as the trigger for the onset of HLH. Vaccination, trauma, surgery and the like can also rarely be triggers.

3. Genetics

Mode of inheritance

All subtypes of FHL (FHL1~5) follow an autosomal recessive mode of inheritance. Carrier parents (each carrying one mutant allele) are clinically normal, but each child has a 25% chance of being affected. The frequency is increased in populations with consanguineous marriage.

Genotype-phenotype correlation

The PRF1 p.A91V polymorphism causes a mild reduction in perforin function; it does not cause FHL on its own, but acts as a predisposing factor when combined with other HLH-related variants. UNC13D mutations are reported relatively frequently in East Asian FHL patients, including in Korea, Japan and China. STX11 and STXBP2 mutations are found more often in patients of Turkish, Arab and Kurdish descent.

Penetrance and age of onset

The penetrance of FHL is very high, and almost all affected individuals develop the disease in childhood. Onset is mostly at age 2 or younger, and with some mild mutations onset may be delayed to adolescence or adulthood.

4. General epidemiology

Incidence

The incidence of primary HLH, including FHL, is estimated at about 1 per 100,000 newborns (i.e., about 1–2 per million), making it an extremely rare disease. A nationwide study in Sweden reported an incidence of pediatric FHL of about 0.3–1.2 per million children per year.

Sex and age distribution

The male-to-female ratio is nearly equal, and more than 80% develop the disease within the first 12 months of life. The frequency increases in populations with a high rate of parental consanguinity.

Situation in Korea

The exact incidence of FHL in Korea has not been established, but multicenter studies by the Korean pediatric hematology-oncology society report dozens of cases of primary HLH, including FHL, each year. With improved access to gene panel testing, the rate of identifying genetic causes is increasing.

5. Pathophysiology

Defects of the perforin-granzyme pathway

In a normal cytotoxic immune response, when CTLs and NK cells recognize target cells (virus-infected cells), they secrete cytotoxic granules into the immunological synapse. Perforin forms pores in the target cell membrane, and granzyme B enters the cell and activates caspases to induce cell death (apoptosis). In FHL, the function of key proteins in this pathway is lost, so target cells are not killed.

Persistent immune activation and cytokine storm

When target cells are not killed, antigen presentation continues and a cycle of mutual activation of T cells and macrophages is maintained. Inflammatory cytokines such as IFN-γ, TNF-α, IL-6, IL-10, IL-18 are secreted explosively, and macrophages become excessively activated, phagocytosing normal blood cells (hemophagocytosis) and causing a systemic inflammatory response.

Multiple organ failure

Vascular endothelial damage due to the cytokine storm, pancytopenia due to hemophagocytosis and disseminated intravascular coagulation (DIC) due to consumption of coagulation factors combine and progress to multiple organ failure.

6. Symptoms

Fever and systemic symptoms

Persistent high fever (38.5℃ or higher) appears as an initial symptom and lasts for days to weeks. Lethargy, loss of appetite and weight loss accompany it. Fever without signs of infection that does not respond to antibiotics is the typical initial symptom of FHL.

Symptoms of cytopenias

Pallor, tachycardia and fatigue due to anemia. Petechiae, ecchymoses and mucosal bleeding due to thrombocytopenia. Increased risk of recurrent infections and sepsis due to neutropenia.

Splenomegaly and hepatomegaly

Splenomegaly is observed in almost all patients with FHL and causes abdominal distension, abdominal pain and early satiety. Hepatomegaly and abnormal liver function are also commonly present.

Neurological symptoms

Neurological symptoms occur in about 30–50% of patients with FHL, and seizures, altered consciousness, irritability, hypotonia, cranial nerve palsies and others may appear. Nervous system involvement markedly worsens the prognosis.

7. Signs

Physical examination findings

The main signs are fever of 38.5℃ or higher, splenomegaly with the splenic tip palpable 3 cm or more below the costal margin, jaundice (scleral icterus) and hepatomegaly. Petechiae and ecchymoses of the skin may be observed. With nervous system involvement, neck stiffness, abnormal reflexes and decreased consciousness are present.

Hematologic and biochemical findings

Cytopenias affecting two or more lineages on complete blood count. Markedly elevated serum ferritin (often 10,000 ng/mL or higher). Elevated serum triglycerides, decreased serum fibrinogen. Elevated AST/ALT, elevated total bilirubin. Markedly elevated soluble CD25 (sIL-2R). Reduced or absent NK cell cytotoxic activity. Reduced or absent perforin expression on flow cytometry (FHL2).

Bone marrow examination

On bone marrow smear, hemophagocytosis is observed, with activated histiocytes phagocytosing red blood cells, platelets, white blood cells and others.

8. Screening

Family history-based screening

Active genetic screening is recommended for siblings of patients with FHL. When a mutation in the causative gene is identified, analysis of the same gene in siblings determines early whether they are affected but asymptomatic.

Early suspicion based on clinical indicators

When unexplained persistent fever, splenomegaly and pancytopenia occur together in an infant (age 2 or younger), FHL should be included first in the differential diagnosis. The risk is higher when there is a family history or the child was born to consanguineous parents.

Biochemical screening indicators

A sharp rise in serum ferritin (>500 ng/mL) is an indication for immediate further testing. NK cell activity testing and confirmation of perforin expression by flow cytometry are useful for screening for FHL.

9. Diagnosis

Applying the HLH-2004 clinical diagnostic criteria

According to the Histiocyte Society's HLH-2004 criteria, HLH (including FHL) is diagnosed when 5 or more of the 8 diagnostic criteria are met or a molecular genetic diagnosis is confirmed.

Molecular genetic diagnosis

FHL is confirmed by identifying mutations in a causative gene (PRF1, UNC13D, STX11, STXBP2). When HLH is clinically suspected and a primary form is possible (age 2 or younger, family history, consanguineous parents, etc.), gene panel NGS testing is performed early in parallel with clinical tests.

Functional tests

Prenatal diagnosis

In families with confirmed FHL, prenatal diagnosis in subsequent pregnancies is possible by fetal genetic testing through chorionic villus sampling (CVS) or amniocentesis.

10. Treatment

HLH-94/2004 induction therapy

The standard induction therapy for FHL is the HLH-94/2004 protocol, an 8-week combination of dexamethasone and etoposide (VP-16). Dexamethasone is given at 10 mg/m²/day for 2 weeks and then tapered, and etoposide is given at 150 mg/m² twice weekly for the first 2 weeks and then once weekly. With central nervous system involvement, intrathecal methotrexate (IT-MTX) and corticosteroids are added.

Hematopoietic stem cell transplantation

The curative treatment of FHL is allogeneic hematopoietic stem cell transplantation (allo-HSCT). An HLA-matched sibling donor (MSD) is most ideal, but if none is available, a matched unrelated donor (MUD) or haploidentical transplant is performed. Reduced-intensity conditioning (RIC) transplantation is used as a strategy to lower toxicity while minimizing graft-versus-host disease (GvHD).

Emapalumab and new treatments

Emapalumab, a humanized monoclonal antibody targeting IFN-γ, received FDA approval in 2018 for children with primary HLH that is refractory to or has relapsed after conventional therapy. It is useful as bridging therapy before HSCT.

11. Prognosis

Prognosis without treatment

Without treatment, FHL is a fatal disease leading to death within weeks to months after diagnosis, and in the past the median survival was less than 2 months. Multiple organ failure and bleeding are the direct causes of death.

Prognosis with the HLH-2004 protocol

In the HLH-94 study, the 5-year overall survival (OS) was about 54%. In patients who received HSCT, the 5-year OS was about 60–70%, and HSCT is the key treatment that determines the long-term prognosis.

Poor prognostic factors

The prognosis is poor with delayed diagnosis, nervous system involvement, incomplete response to initial induction therapy, infectious complications and PRF1 null mutations.

12. Prevention

Genetic counseling and family screening

Early genetic analysis is performed in siblings of patients with confirmed FHL and in siblings born later to determine whether they are affected but asymptomatic. When both parents are carriers, prenatal genetic testing and preimplantation genetic testing (PGT-M) are recommended in subsequent pregnancies.

Infection prevention and early response

In patients with FHL and during the period before immune recovery after HSCT, viral infections such as EBV, CMV and HSV are prevented, and intensive treatment is started early when infection occurs. Infection risk is minimized through vaccination (excluding live vaccines).

Early diagnosis and prompt initiation of treatment

When fever, pancytopenia and splenomegaly occur together in an infant, HLH differential diagnostic testing is performed immediately, and when FHL is strongly suspected, treatment is started early even before the diagnosis is confirmed, to prevent progression to multiple organ failure.

13. References

  1. Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis. Arch Dis Child. 1952;27(136):519-525.
  2. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957-1959.
  3. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
  4. Janka GE, Lehmberg K. Hemophagocytic syndromes - an update. Blood Rev. 2014;28(4):135-142.
  5. Meeths M, Horne A, Sabel M, et al. Incidence and clinical presentation of primary hemophagocytic lymphohistiocytosis in Sweden. Pediatr Blood Cancer. 2015;62(2):346-352.
  6. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811-1822.
  7. Marsh RA, Vaughn G, Kim MO, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116(26):5824-5831.
  8. Pachlopnik Schmid J, Côte M, Ménager MM, et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev. 2010;235(1):10-23.
  9. Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135(16):1332-1343.
  10. Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728-2738.
  11. Kim HJ, Lee JW, Kim NH, et al. Hemophagocytic lymphohistiocytosis in Korean children: clinical features, genetic basis, and treatment outcome. Blood Res. 2019;54(1):45-52.
  12. Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S82-89.